Could this Energy Stock really climb 74.36% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- February 29, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it. [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- [Tidewater Inc.]( Symbol: [TDW]( Recent Price: $70.37 Average Analyst Price Target: $88.25 (25.41%) Market Cap: $3.72B Last Year's EPS: $0.43 Consensus EPS Forecast: $1.45 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Don Crist, analyst at Johnson Rice, reiterates coverage on [Tidewater Inc. (TDW)]( in the Energy sector with a Buy rating and a price target of $88 (2 weeks ago). [TipRanks.com]( also reports that [Tidewater Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $88.25 . The target pricing ranges from a high forecast of $90 down to a low forecast of $85. [Tidewater Inc. (TDW)](’s last closing price was $70.37 which would put the average price target at 25.41% upside. Here are 3rd party ratings for [TDW](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Bottom 9% (228 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Transform your 401K with Gold (free guide)]( volatility could wipe out your 401K overnight. But if you roll that over into a Gold IRA (which saves you money and taxes), you could actually grow your wealth instead. Download this free gold guide from America’s #1 gold company to take control of your financial future in these uncertain times. Act now for a safer, more stable investment. [Claim your free gold guide today!]( --------------------------------------------------------------- [Biodesix, Inc.]( Symbol: [BDSX]( Recent Price: $1.53 Average Analyst Price Target: $3.50 (128.76%) Market Cap: $137.98M Last Year's EPS: $-0.17 Consensus EPS Forecast: $-0.15 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Kyle Mikson, analyst at Canaccord Genuity, reiterates coverage on [Biodesix, Inc. (BDSX)]( in the Healthcare sector with a Buy rating and a price target of $3.5 (2 months ago). [TipRanks.com]( also reports that [Biodesix, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $3.50 . The target pricing ranges from a high forecast of $3.5 down to a low forecast of $3.5. [Biodesix, Inc. (BDSX)](’s last closing price was $1.53 which would put the average price target at 128.76% upside. Here are 3rd party ratings for [BDSX](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 32% (80 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [inTEST Corporation]( Symbol: [INTT]( Recent Price: $11.53 Average Analyst Price Target: $22.67 (96.59%) Market Cap: $140.22M Last Year's EPS: $0.28 Consensus EPS Forecast: $0.25 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Jaeson Schmidt, analyst at Lake Street, reiterates coverage on [inTEST Corporation (INTT)]( in the Technology sector with a Buy rating and a price target of $19 (2 days ago). [TipRanks.com]( also reports that [inTEST Corporation]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $22.67 . The target pricing ranges from a high forecast of $29 down to a low forecast of $19. [inTEST Corporation (INTT)](’s last closing price was $11.53 which would put the average price target at 96.59% upside. Here are 3rd party ratings for [INTT](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 28% (179 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- [Compass Therapeutics, Inc.]( Symbol: [CMPX]( Recent Price: $1.74 Average Analyst Price Target: $9.00 (417.24%) Market Cap: $221.83M Last Year's EPS: $-0.09 Consensus EPS Forecast: $-0.11 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Compass Therapeutics, Inc. (CMPX)]( in the Healthcare sector with a Buy rating and a price target of $10 (1 month ago). [TipRanks.com]( also reports that [Compass Therapeutics, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $9.00 . The target pricing ranges from a high forecast of $8 down to a low forecast of $10. [Compass Therapeutics, Inc. (CMPX)](’s last closing price was $1.74 which would put the average price target at 417.24% upside. Here are 3rd party ratings for [CMPX](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Top 34% (85 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Ur-Energy Inc.]( Symbol: [URG]( Recent Price: $1.57 Average Analyst Price Target: $2.74 (74.36%) Market Cap: $417.60M Last Year's EPS: $-0.03 Consensus EPS Forecast: $-0.00438 Expected Earnings Date: Mar 01, 2024 Recent Analyst Action: Matt Key, analyst at B.Riley Financial, reiterates coverage on [Ur-Energy Inc. (URG)]( in the Energy sector with a Buy rating and a price target of $3 (3 weeks ago). [TipRanks.com]( also reports that [Ur-Energy Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $2.74 . The target pricing ranges from a high forecast of $3 down to a low forecast of $2.5. [Ur-Energy Inc. (URG)](’s last closing price was $1.57 which would put the average price target at 74.36% upside. Here are 3rd party ratings for [URG](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Bottom 41% (147 out of 250) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time. [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software